ClinicalTrials.gg
RecruitingNCT05805384Updated Nov 12, 2026

Evaluating a Noise Reduction Algorithm With Cochlear Implant Users

An interventional study of SEDA in Hearing Impairment, sponsored by NYU Langone Health. Recruiting at 1 site in United States. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by NYU Langone Health · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2023; still recruiting 3 years 8 months later.
Updated Nov 12, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Not applicable
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Hearing Loss by NYU Langone Health — 6 open to participants now, 6 under way, none of them phase 3. Hearing Loss · NYU Langone Health.

Planned enrollment
Largest of 10
60 · median 14
Started
2023
with 1 other
No phase
10 of 10
6 open now
Registered
6th of 10
by date

Among the 10 studies in Hearing Loss by NYU Langone Health, this one has the largest planned enrollment, is one of 2 that started in 2023, is one of 10 with no phase, and was the 6th registered.

Hearing Loss

797 studies on the registry are indexed under Hearing Loss; 194 are open to participants now.

Browse Hearing Loss studies →

Open to participants now

6 of the 10 studies in Hearing Loss by NYU Langone Health are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 125 Hearing Loss studies recruiting now, 60 (48%) set no upper age limit and 43 (34%) stop at 75 or younger; 47 take children under 18; 46 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Hearing Loss by NYU Langone Health, or all of them as a file.
02

Study summary

In this study, a noise reduction algorithm will be implemented in various listening situations to evaluate its effectiveness in improving speech understanding for cochlear implant users ages 12 and older.

03

Conditions studied

  • Hearing Impairment

Browse trials for

04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • At least 12 years of age.
  • Be post-lingually deafened cochlear implant recipients with at least 6 months experience regardless of manufacturer.
  • The PI must also deem the child to be developmentally able to complete the experiments.

Exclusion criteria

Exclusion Criteria:

  • Anyone who is not a cochlear implant user or is aged under 12 years.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Cochlear Implant Users

    Participants will complete up to 4 experiments evaluating the use of the Speech Enhancement using Dynamic thresholding Approach (SEDA) algorithm. Each testing session will take between 4-6 hours to complete. Testing sessions will continue until the completion of the experiments.

    Device: SEDA

Interventions

  • DeviceSEDA

    Speech Enhancement using Dynamic thresholding Approach (SEDA) is a software algorithm that removes background noise.

06

What researchers measure

Primary outcomes

  1. Percent of Words Correctly Recognized in Noisy Conditions with SEDA NR

    Participants will listen to sentences and repeat all the words they heard. This outcome measures the percent of words correctly recognized in noisy listening conditions while using the SEDA Noise Reduction (NR) algorithm.

    Time frame: Up to Year 2 (Completion of Experiment 1.1)

  2. Percent of Words Correctly Recognized in Noisy Conditions without NR

    Participants will listen to sentences and repeat all the words they heard. This outcome measures the percent of words correctly recognized in noisy listening conditions without SEDA NR.

    Time frame: Up to Year 2 (Completion of Experiment 1.1)

  3. Percent of Words Correctly Recognized in Quiet Conditions with SEDA NR

    Participants will listen to sentences and repeat all the words they heard. This outcome measures the percent of words correctly recognized in quiet listening conditions while using the SEDA NR.

    Time frame: Up to Year 2 (Completion of Experiment 1.1)

  4. Percent of Words Correctly Recognized in Quiet Conditions without NR

    Participants will listen to sentences and repeat all the words they heard. This outcome measures the percent of words correctly recognized in quiet listening conditions with SEDA NR.

    Time frame: Up to Year 2 (Completion of Experiment 1.1)

  5. Visual Analogue Scale (VAS) Rating of SEDA NR

    Participants will be presented with two buttons: one button will play a sample with SEDA NR and the other will play a sample without SEDA NR. Listeners will report which sample was preferable by clicking on a horizontal visual analog scale (VAS). VAS ratings will be scored on a scale of -10 to 10 where positive numbers indicate a preference for SEDA NR and negative numbers indicate a preference for not using SEDA NR. The magnitude of the absolute value of the score indicates the strength of the preference.

    Time frame: Up to Year 2 (Completion of Experiment 1.2)

  6. Percent of Words Correctly Recognized in Noisy Conditions with Clinical NR

    Participants will listen to sentences and repeat all the words they heard. This outcome measures the percent of words correctly recognized in noisy listening conditions while using a clinical NR algorithm.

    Time frame: Up to Year 2 (Completion of Experiment 2)

  7. Percent of Words Correctly Recognized in Quiet Conditions with Clinical NR

    Participants will listen to sentences and repeat all the words they heard. This outcome measures the percent of words correctly recognized in quite listening conditions while using a clinical NR algorithm.

    Time frame: Up to Year 2 (Completion of Experiment 2)

  8. Percent of Words Correctly Recognized with no SEDA NR

    Participants will listen to sentences and repeat all the words they heard. This outcome measures the percent of words correctly recognized without SEDA NR.

    Time frame: Up to Year 2 (Completion of Experiment 4)

  9. Percent of Words Correctly Recognized with Standard SEDA NR

    Participants will listen to sentences and repeat all the words they heard. This outcome measures the percent of words correctly recognized with Standard SEDA NR.

    Time frame: Up to Year 2 (Completion of Experiment 4)

  10. Percent of Words Correctly Recognized with Low-Computation SEDA NR

    Participants will listen to sentences and repeat all the words they heard. This outcome measures the percent of words correctly recognized with the Low-Computation SEDA NR, which is designed to have minimal computation while maintaining an Extended Short-Time Objective Intelligibility Predictor (ESTOI) value similar to the "standard" SEDA implementation

    Time frame: Up to Year 2 (Completion of Experiment 4)

  11. Percent of Words Correctly Recognized with Very Low-Computation SEDA NR

    Participants will listen to sentences and repeat all the words they heard. This outcome measures the percent of words correctly recognized with the Very Low-Computation SEDA NR, which is designed to have a reasonable ESTOI value with minimal computational requirements.

    Time frame: Up to Year 2 (Completion of Experiment 4)

07

Study locations

1 of 1 sites recruiting
  • Tisch Hospital
    New York, New York 10016, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — The de-identified participant data from the final research dataset used in the published manuscript will be shared upon reasonable request beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research provided the investigator who proposes to use the data executes a data use agreement with NYU Langone Health. Requests may be directed to: David.landsberger@nyulangone.com. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.

Supporting information: Study protocol, Statistical analysis plan

Time frame: Beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research.

Access criteria: The investigator who proposed to use the data will be granted access upon reasonable request. Requests should be directed to David.landsberger@nyulangone.com. To gain access, data requestors will need to sign a data access agreement.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2023 (actual). Primary completion is estimated for Nov 2027, 56 months after the start.

Of 197 non-industry interventional studies with no phase under Hearing Loss, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 59. This study's planned 56 months is above that.

Counting every sponsor, half of 323 studies reached it within 19 months; a quarter within 5 and three quarters within 42.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 12, 2026: primary completion Mar 2027 → Nov 2027 and completion Mar 2027 → Nov 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 23, 2023
First posted
Apr 10, 2023
StartActual
Mar 1, 2023
Primary completionEst.
Nov 1, 2027was Mar 2027
CompletionEst.
Nov 1, 2027was Mar 2027
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Mar 1, 2027→Nov 1, 2027
Nov 12, 2026
Study completion
Mar 1, 2027→Nov 1, 2027
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    Primary completion Mar 1, 2027→Nov 1, 2027
    Study completion Mar 1, 2027→Nov 1, 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05805384
Lead sponsor
NYU Langone Health
Responsible party
Sponsor
First posted
Apr 10, 2023
Start date
Mar 1, 2023
Primary completion
Nov 1, 2027 (estimated)
Completion
Nov 1, 2027 (estimated)
Last update
Nov 12, 2026

Study contacts

David M. Landsberger
Contact
David.landsberger@nyulangone.com
212-263-8455
Natalia Stupak
Contact
Natalia.stupak@nyulangone.org
646-501-4153
David M. Landsberger
principal investigator · NYU Langone Health

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion